Bibliography: library/10665-357088

The reference for library/10665-357088 (who-iris) and any references extracted from it. library · All references.

Export these 90 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD

✍ + Add reference (standalone node)

Build a standalone folio-reference/v1 node at references/reference.jsonld from fields or pasted BibTeX / CSL-JSON.



· ✍ Create standalone node on GitHub · Download .jsonld · Download .csl.json ·

90 shown

  1. World Health Organization (2022). Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. World Health Organization.
    10665-357088 · catalogue · link · repository record · ISBN 9789240052178 (electronic version) · source: catalogue/records/10665-357088.dc.json · held: library/10665-357088
    export: BibTeX · RIS · CSL-JSON · DC XML
  2. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017 (https://apps.who.int/iris/handle/10665/255884, accessed 9 March 2022).
    · extracted · link · source: references/10665-357088.sec-033.1.json
  3. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17:873–81.
    · extracted · source: references/10665-357088.sec-033.2.json
  4. Tenforde MW, Shapiro AE, Rouse B, Jarvis JN, Li T, Eshun-Wilson I et al. Treatment for HIV-associated cryptococcal meningitis. Cochrane Database Syst Rev. 2018;7:CD005647.
    · extracted · source: references/10665-357088.sec-033.3.json
  5. Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV. 2015;2:e438–44.
    · extracted · source: references/10665-357088.sec-033.4.json
  6. Pasquier E, Kunda J, De Beaudrap P, Loyse A, Temfack E, Molloy SF et al. Long-term mortality and disability in cryptococcal meningitis: a systematic literature review. Clin Infect Dis. 2018;66:1122–32.
    · extracted · source: references/10665-357088.sec-033.5.json
  7. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol. 1999;37:3204–9.
    · extracted · source: references/10665-357088.sec-033.6.json
  8. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS – 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev. 1995;8:515–48.
    · extracted · source: references/10665-357088.sec-033.7.json
  9. Speed BR, Kaldor J. Rarity of cryptococcal infection in children. Pediatr Infect Dis J. 1997;16:536–7.
    · extracted · source: references/10665-357088.sec-033.8.json
  10. Gonzalez CE, Shetty D, Lewis LL, Mueller BU, Pizzo PA, Walsh TJ. Cryptococcosis in human immunodeficiency virus–infected children. Pediatr Infect Dis J. 1996;15:796–800.
    · extracted · source: references/10665-357088.sec-033.9.json
  11. Meiring ST, Quan VC, Cohen C, Dawood H, Karstaedt AS, McCarthy KM et al. A comparison of cases of paediatric-onset and adult-onset cryptococcosis detected through population-based surveillance, 2005–2007. AIDS. 2012;26:2307–14.
    · extracted · source: references/10665-357088.sec-033.10.json
  12. Loyse A, Dromer F, Day J, Lortholary O, Harrison TS. Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother. 2013;68:2435–44.
    · extracted · source: references/10665-357088.sec-033.11.json
  13. Lightowler JV, Cooke GS, Mutevedzi P, Lessells RJ, Newell ML, Dedicoat M. Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa. PLoS One. 2010;5:e8630.
    · extracted · source: references/10665-357088.sec-033.12.json
  14. Kambugu A, Meya DB, Rhein J, O’Brien M, Janoff EN, Ronald AR et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008;46:1694–701.
    · extracted · source: references/10665-357088.sec-033.13.json
  15. Bicanic T, Brouwer AE, Meintjes G, Rebe K, Limmathurotsakul D, Chierakul W et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS. 2009;23:701–6.
    · extracted · source: references/10665-357088.sec-033.14.json
  16. Graybill JR, Sobel J, Saag M, van Der Horst C, Powderly W, Cloud G et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000;30:47–54.
    · extracted · source: references/10665-357088.sec-033.15.json
  17. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva: World Health Organization; 2018 (https://www.who.int/publications/i/item/9789241550277, accessed 9 March 2022).
    · extracted · link · source: references/10665-357088.sec-033.16.json
  18. Rolfes MA, Hullsiek KH, Rhein J, Nabeta HW, Taseera K, Schutz C et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis. 2014;59:1607–14.
    · extracted · source: references/10665-357088.sec-033.17.json
  19. Likasitwattanakul S, Poneprasert B, Sirisanthana V. Cryptococcosis in HIV-infected children. Southeast Asian J Trop Med Public Health. 2004;35:935–9.
    · extracted · source: references/10665-357088.sec-033.18.json
  20. Abadi J, Nachman S, Kressel AB, Pirofski L. Cryptococcosis in children with AIDS. Clin Infect Dis. 1999;28:309–13.
    · extracted · source: references/10665-357088.sec-033.19.json
  21. Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015;385:2173–82.
    · extracted · source: references/10665-357088.sec-033.20.json
  22. Govender NP, Meintjes G, Mangena P, Nel J, Potgieter S, Reddy D et al. Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. South Afr J HIV Med. 2019;20:1030.
    · extracted · source: references/10665-357088.sec-033.21.json
  23. Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C et al. CD4 cell count threshold for cryptococcal antigen screening of HIV-infected individuals: a systematic review and meta-analysis. Clin Infect Dis. 2018;66(Suppl. 2):S152–9.
    · extracted · source: references/10665-357088.sec-033.22.json
  24. Awotiwon AA, Johnson S, Rutherford GW, Meintjes G, Eshun-Wilson I. Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people. Cochrane Database Syst Rev. 2018;8:CD004773.
    · extracted · source: references/10665-357088.sec-033.23.json
  25. Jarvis JN, Harrison TS, Lawn SD, Meintjes G, Wood R, Cleary S. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS One. 2013;8:e69288.
    · extracted · source: references/10665-357088.sec-033.24.json
  26. Cassim N, Schnippel K, Coetzee LM, Glencross DK. Establishing a cost-per-result of laboratory-based, reflex cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/µl using a lateral flow assay (LFA) at a typical busy CD4 laboratory in South Africa. PLoS One. 2017;12:e0171675.
    · extracted · source: references/10665-357088.sec-033.25.json
  27. Chipungu C, Veltman JA, Jansen P, Chiliko P, Lossa C, Namarika D et al. Feasibility and acceptability of cryptococcal antigen screening and prevalence of cryptocococcemia in patients attending a resource-limited HIV/AIDS clinic in Malawi. J Int Assoc Provid AIDS Care. 2015;14:387–90.
    · extracted · source: references/10665-357088.sec-033.26.json
  28. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A et al. Cost– effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count ≤100 cells/µL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51:448–55.
    · extracted · source: references/10665-357088.sec-033.27.json
  29. Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr. 2012;59:e85–91.
    · extracted · source: references/10665-357088.sec-033.28.json
  30. Smith RM, Nguyen TA, Ha HT, Thang PH, Thuy C, Lien TX et al. Prevalence of cryptococcal antigenemia and cost–effectiveness of a cryptococcal antigen screening program – Vietnam. PLoS One. 2013;8:e62213.
    · extracted · source: references/10665-357088.sec-033.29.json
  31. Vidal JE, Toniolo C, Paulino A, Colombo A, Dos Anjos Martins M, da Silva Meira C et al. Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil. Trop Med Int Health. 2016;21:1539–44.
    · extracted · source: references/10665-357088.sec-033.30.json
  32. Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med. 2017;377:233–45.
    · extracted · source: references/10665-357088.sec-033.31.json
  33. Parkes-Ratanshi R, Wakeham K, Levin J, Namusoke D, Whitworth J, Coutinho A et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis. 2011;11:933–41.
    · extracted · source: references/10665-357088.sec-033.32.json
  34. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. 1997;11:1463–71.
    · extracted · source: references/10665-357088.sec-033.33.json
  35. Hamill RJ, Sobel JD, El-Sadr W, Johnson PC, Graybill JR, Javaly K et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis. 2010;51:225–32.
    · extracted · source: references/10665-357088.sec-033.34.json
  36. Botero Aguirre JP, Restrepo Hamid AM. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database Syst Rev. 2015;11:CD010481.
    · extracted · source: references/10665-357088.sec-033.35.json
  37. Beyene T, Zewde AG, Balcha A, Hirpo B, Yitbarik T, Gebissa T et al. Inadequacy of high-dose fluconazole monotherapy among cerebrospinal fluid cryptococcal antigen (CrAg)-positive human immunodeficiency virus–infected persons in an Ethiopian CrAg screening program. Clin Infect Dis. 2017;65:2126–9.
    · extracted · source: references/10665-357088.sec-033.36.json
  38. Gaskell KM, Rothe C, Gnanadurai R, Goodson P, Jassi C, Heyderman RS et al. A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi. PLoS One. 2014;9:e110285.
    · extracted · source: references/10665-357088.sec-033.37.json
  39. Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E et al. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. N Engl J Med 2022. 386(12):1109-1120.
    · extracted · source: references/10665-357088.sec-033.38.json
  40. Mehta P, Vinks A, Filipovich A, Vaughn G, Fearing D, Sper C et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2006;12:235–40.
    · extracted · source: references/10665-357088.sec-033.39.json
  41. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M et al. GRADE guidelines. 8. Rating the quality of evidence – indirectness. J Clin Epidemiol. 2011;64:1303–10.
    · extracted · source: references/10665-357088.sec-033.40.json
  42. Fleury M, Fonzo-Christe C, Normand C, Bonnabry P. Confusion between two amphotericin B formulations leading to a paediatric rehospitalisation. Drug Saf Case Rep. 2016;3:4.
    · extracted · source: references/10665-357088.sec-033.41.json
  43. Lawrence DS, Tsholo K, Ssali A, Mupambireyi Z, Hoddinott G, Nyirenda D et al. The Lived Experience Of Participants in an African RandomiseD trial (LEOPARD): protocol for an in-depth qualitative study within a multisite randomised controlled trial for HIV-associated cryptococcal meningitis. BMJ Open. 2021;11:e039191.
    · extracted · source: references/10665-357088.sec-033.42.json
  44. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/345533, accessed 9 March 2022).
    · extracted · link · source: references/10665-357088.sec-033.43.json
  45. Liposomal amphotericin B: solving the access puzzle. Geneva: Médecins Sans Frontières; 2021 (https://msfaccess.org/liposomal-amphotericin-b-solving-access-puzzle, accessed 9 March 2022).
    · extracted · link · source: references/10665-357088.sec-033.44.json
  46. HIV Drug Interactions, University of Liverpool [website]. Liverpool: University of Liverpool, 2022 (https://www.hiv-druginteractions.org/prescribing-resources, accessed 9 March 2022).
    · extracted · link · source: references/10665-357088.sec-033.45.json
  47. Aguirre JPB, Hamid AMR. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database Syst Rev. 2015;11:CD010481.
    · extracted · source: references/10665-357088.sec-033.46.json
  48. Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45:737–79.
    · extracted · source: references/10665-357088.sec-033.47.json
  49. Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Choksawadphinyo K. The efficacy of fluconazole 600 mg/day versus itraconazole 600 mg/day as consolidation therapy of cryptococcal meningitis in AIDS patients. J Med Assoc Thai. 2003;86:293–8.
    · extracted · source: references/10665-357088.sec-033.48.json
  50. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997;337:15–21.
    · extracted · source: references/10665-357088.sec-033.49.json
  51. Cryptococcosis. Brussels: European AIDS Clinical Society; 2022 (https://eacs.sanfordguide.com/ois/cryptococcosis, accessed 9 March 2022).
    · extracted · link · source: references/10665-357088.sec-033.50.json
  52. Bozzette SA, Larsen RA, Chiu J, Leal MA, Jacobsen J, Rothman P et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 1991;324:580–4.
    · extracted · source: references/10665-357088.sec-033.51.json
  53. Saag MS, Cloud GA, Graybill JR, Sobel JD, Tuazon CU, Johnson PC et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1999;28:291–6.
    · extracted · source: references/10665-357088.sec-033.52.json
  54. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med. 1992;326:793–8.
    · extracted · source: references/10665-357088.sec-033.53.json
  55. Troncoso A, Fumagalli J, Shinzato R, Gulotta H, Toller M, Bava J. CNS cryptococcoma in an HIV-positive patient. J Int Assoc Physicians AIDS Care (Chic). 2002;1:131–3.
    · extracted · source: references/10665-357088.sec-033.54.json
  56. Velamakanni SS, Bahr NC, Musubire AK, Boulware DR, Rhein J, Nabeta HW. Central nervous system cryptococcoma in a Ugandan patient with human immunodeficiency virus. Med Mycol Case Rep. 2014;6:10–3.
    · extracted · source: references/10665-357088.sec-033.55.json
  57. Klock C, Cerski M, Goldani LZ. Histopathological aspects of neurocryptococcosis in HIV-infected patients: autopsy report of 45 patients. Int J Surg Pathol. 2009;17:444–8.
    · extracted · source: references/10665-357088.sec-033.56.json
  58. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O, French Cryptococcosis Study Group. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4:e21.
    · extracted · source: references/10665-357088.sec-033.57.json
  59. Charlier C, Dromer F, Leveque C, Chartier L, Cordoliani YS, Fontanet A et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS One. 2008;3:e1950.
    · extracted · source: references/10665-357088.sec-033.58.json
  60. Loyse A, Moodley A, Rich P, Molloy SF, Bicanic T, Bishop L et al. Neurological, visual, and MRI brain scan findings in 87 South African patients with HIV-associated cryptococcal meningoencephalitis. J Infect. 2015;70:668–75.
    · extracted · source: references/10665-357088.sec-033.59.json
  61. Zhang Z, Zhang X, Zhou YY, Jiang CM, Jiang HY. The safety of oral fluconazole during the first trimester of pregnancy: a systematic review and meta-analysis. BJOG. 2019;126:1546–52.
    · extracted · source: references/10665-357088.sec-033.60.json
  62. Beardsley J, Wolbers M, Kibengo FM, Ggayi AB, Kamali A, Cuc NT et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med. 2016;374:542–54.
    · extracted · source: references/10665-357088.sec-033.61.json
  63. Eshun-Wilson I, Okwen MP, Richardson M, Bicanic T. Early versus delayed antiretroviral treatment in HIV positive people with cryptococcal meningitis. Cochrane Database Syst Rev. 2018;(7):CD009012. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV
    · extracted · source: references/10665-357088.sec-033.62.json
  64. Sun HY, Hung CC, Chang SC. Management of cryptococcal meningitis with extremely high intracranial pressure in HIV-infected patients. Clin Infect Dis. 2004;38:1790–2.
    · extracted · source: references/10665-357088.sec-033.63.json
  65. Meda J, Kalluvya S, Downs JA, Chofle AA, Seni J, Kidenya B et al. Cryptococcal meningitis management in Tanzania with strict schedule of serial lumber punctures using intravenous tubing sets: an operational research study. J Acquir Immune Defic Syndr. 2014;66:e31–6.
    · extracted · source: references/10665-357088.sec-033.64.json
  66. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291–322.
    · extracted · source: references/10665-357088.sec-033.65.json
  67. Newton PN, Thai le H, Tip NQ, Short JM, Chierakul W, Rajanuwong A et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis. 2002;35:769–72.
    · extracted · source: references/10665-357088.sec-033.66.json
  68. Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis. 2010;10:791–802.
    · extracted · source: references/10665-357088.sec-033.67.json
  69. Shelburne SA, 3rd, Darcourt J, White AC, Jr., Greenberg SB, Hamill RJ, Atmar RL et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:1049–52.
    · extracted · source: references/10665-357088.sec-033.68.json
  70. Larson BA, Rockers PC, Bonawitz R, Sriruttan C, Glencross DK, Cassim N et al. Screening HIV-infected patients with low CD4 counts for cryptococcal antigenemia prior to initiation of antiretroviral therapy: cost effectiveness of alternative screening strategies in South Africa. PLoS One. 2016;11:e0158986.
    · extracted · source: references/10665-357088.sec-033.69.json
  71. Vallabhaneni S, Longley N, Smith M, Smith R, Osler M, Kelly N et al. Implementation and operational research: evaluation of a public-sector, provider-initiated cryptococcal antigen screening and treatment program, Western Cape, South Africa. J Acquir Immune Defic Syndr. 2016;72:e37–42.
    · extracted · source: references/10665-357088.sec-033.70.json
  72. Rick F, Niyibizi AA, Shroufi A, Onami K, Steele SJ, Kuleile M et al. Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: A feasibility study in rural Lesotho. PLoS One. 2017;12:e0183656.
    · extracted · source: references/10665-357088.sec-033.71.json
  73. Antifungal drug maps [website]. Geneva: Global Action Fund for Fungal Infections; 2018 (http://www.gaffi.org/antifungal-drug-maps, accessed 9 March 2022).
    · extracted · link · source: references/10665-357088.sec-033.72.json
  74. Loyse A, Thangaraj H, Easterbrook P, Ford N, Roy M, Chiller T et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis. 2013;13:629–37.
    · extracted · source: references/10665-357088.sec-033.73.json
  75. Smilnak GJ, Charalambous LT, Cutshaw D, Premji AM, Giamberardino CD, Ballard CG et al. Novel treatment of cryptococcal meningitis via neurapheresis therapy. J Infect Dis. 2018;218:1147–54.
    · extracted · source: references/10665-357088.sec-033.74.json
  76. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342899, accessed 9 March 2022).
    · extracted · link · source: references/10665-357088.sec-033.75.json
  77. Global AIDS Monitoring [website]. Geneva: UNAIDS; 2022 (https://www.unaids.org/en/global-aids-monitoring, accessed 9 March 2022). Recommendation Recommended in 2012 Updated in 2018 Updated in 2022
    · extracted · link · source: references/10665-357088.sec-033.76.json
  78. Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E, et al. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. N Engl J Med 2022. 386(12):1109-1120.
    · extracted · source: references/10665-357088.sec-035.1.json
  79. Lawrence DS, Tsholo K, Ssali A, Mupambireyi Z, Hoddinott G, Nyirenda D et al. The Lived Experience Of Participants in an African RandomiseD trial (LEOPARD): protocol for an in-depth qualitative study within a multisite randomised controlled trial for HIV-associated cryptococcal meningitis. BMJ Open. 2021;11:e039191.
    · extracted · source: references/10665-357088.sec-035.2.json
  80. Liposomal amphotericin B: solving the access puzzle. Geneva: Médecins Sans Frontières; 2021 (https://msfaccess.org/liposomal-amphotericin-b-solving-access-puzzle, accessed 9 March 2022).
    · extracted · link · source: references/10665-357088.sec-035.3.json
  81. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17:873–81.
    · extracted · source: references/10665-357088.sec-047.1.json
  82. Tenforde MW, Shapiro AE, Rouse B, Jarvis JN, Li T, Eshun-Wilson I et al. Treatment for HIV-associated cryptococcal meningitis. Cochrane Database Syst Rev. 2018;(7):CD005647.
    · extracted · source: references/10665-357088.sec-047.2.json
  83. Diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children: policy brief. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/handle/10665/260400, ac cessed 29 March 2022).
    · extracted · link · source: references/10665-357088.sec-047.3.json
  84. Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. N Engl J Med. 2018;378:1004– 17.
    · extracted · source: references/10665-357088.sec-047.4.json
  85. Tenforde MW, Gertz AM, Lawrence DS, Wills NK, Guthrie BL, Farquhar C et al. Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis. J Int AIDS Soc. 2020;23:e25416.
    · extracted · source: references/10665-357088.sec-047.5.json
  86. Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E, et al. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. N Engl J Med 2022. 386(12):1109-1120.
    · extracted · source: references/10665-357088.sec-047.6.json
  87. National Institute of Allergy and Infectious Diseases, Division of AIDS. Table for grading the severity of adult and pediatric adverse events. Washington (DC): United States Department of Health and Human Services; 2017 (https://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-tables, accessed 29 March 2022).
    · extracted · link · source: references/10665-357088.sec-047.7.json
  88. Covidence systematic review software. Melbourne: Veritas Health Innovation; 2022 (https://www.covidence.org, accessed 29 March 2022).
    · extracted · link · source: references/10665-357088.sec-047.8.json
  89. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al. Cochrane handbook for systematic reviews of interventions, version 6.2. London: Cochrane; 2021.
    · extracted · source: references/10665-357088.sec-047.9.json
  90. Shroufi A, Chiller T, Jordan A, Denning DW, Harrison TS, Govender NP et al. Ending deaths from HIV-related cryptococcal meningitis by 2030. Lancet Infect Dis. 2021;21:16–8.
    · extracted · source: references/10665-357088.sec-047.10.json